This paper explores the potential of polyethylene glycol enclatherated pectin-mucin (PEGencl-PEC:MUC) submicron matrices (SMMs) as an intravaginal drug delivery system capable of delivering an anti-HIV-1 agent (zidovudine; AZT) over a prolonged duration. A three factor and three level ( 
Introduction
Focus on preventing vaginal HIV-1 transmission has led to the development and usage of a physical polymeric barrier/sheath commonly known as a condom which is worn during coitus to prevent the mixing of male and female reproductive fluids thus preventing HIV-1 infection.
Though largely effective in preventing HIV-1 transmission, the condom has been hampered by inappropriate, infrequent usage and to some extent it has suffered problems of cultural and religious acceptability. As an alternative to the condoms, contemporary research is being done on microbicides. These are anti-HIV-1 agents that may be applied topically to the vaginal or rectal cavity to prevent HIV-1 transmission (Stone, 2002; Woolfson et al., 2010) . A keen interest in using antiretroviral drugs as microbicides has also emerged given their success in treating HIV/AIDS (Klaase et al., 2008) . Although microbicides hold much promise and their concept is sound, clinical trials conducted up-to-date have failed to demonstrate efficacy (Hendrix et al., 2009) . Several questions have been raised and some answers postulated to try end explain why anti-HIV-1 agents effective in vitro have failed to demonstrate efficacy in vivo. One common possible explanation given is microbicide formulations did not take into consideration and did not address some fundamental anatomical, physiochemical and physiological principles involved in vaginal HIV-1 transmission. Such factors include; the need to maintain or augment the vaginal mucosal barrier properties, maintenance of the HIV-1 prohibitive acidic pH (~4.5) of the vaginal cavity, presence of the anti-HIV-1 agent in appropriate quantities in the vaginal cavity where it has to be distributed extensively and exhaustively on the vaginal mucosa, anti-HIV-1 agent presence in the sub-epithelia to counteract HIV-1 that would have transcytosed the vaginal epithelia and having the microbicide stays at the site for a longer duration than HIV-1 (Hendrix et al., 2009 ).
The development of topically applied chemical agents that may effectively prevent vaginal HIV-1 transmission (microbicides) has been a major challenge for pharmaceutical scientists (Hendrix et al., 2009; Adams and Kashuba, 2012; Pillay et al., 2012) . The difficulties have included; microbicide acceptance as an alternative HIV-1 prevention modality, pharmacokinetic inadequacy whereby the microbicide has to be distributed throughout the vaginal mucosa in sufficient quantities to prevent HIV-1 transmission and mucosal toxicity which diminishes the vaginal mucosa's barrier properties resulting in easy HIV-1 mucosal transcytosis and transmission (Adams and Kashuba, 2012; Pillay et al., 2012) . Despite having vast potential as a preventative tool against vaginal HIV-1 transmission, research conducted thus far has failed to provide an effective anti-HIV-1 microbicide product to the market. Various formulations have been prepared to try and mitigate these concerns, among them; gels, creams, films, tablets and rings (Hendrix et al., 2009) . Gels, creams and films are indiscrete, sticky and are short acting thus require frequent application before and after every coital act whilst tablets and rings are discrete and may be formulated to deliver the anti-HIV-1 agent over an extended duration (Klaase et al., 2008) . In this study, poly(ethylene glycol) enclatherated pectin-mucin submicron matrices (SMMs) were formulated for potential inclusion into a polymeric caplet eventually forming a composite polymeric drug delivery system as a potential microbicide drug delivery system. The submicron matrices were formulated from biocompatible materials; pectin, porcine gastric mucin and polyethylene glycol. These polymers formed the framework structure of the submicron matrices enabling the encapsulation and controlled release of zidovudine, the model antiretroviral used in this study. was prepared from analytical grade reagents in accordance to Owen and Katz's formulation (Owen and Katz, 1999) .
Materials and Methods

Materials
Box-Behnken design approach for the preparation of PEG-encl-PEC:MUC SMMs
A three-factor, three-level (3
College, Pennsylvania, USA) was employed to optimize the preparation of AZT-loaded PEGencl-PEC:MUC SMMs (Karnachi and Khan, 1996; Box and Behnken, 1960) . Upper and lower levels of three independent parameters that included; ultrasonication time (ST), surfactant concentration (SC) and drug:polymer (D:P) ratio were chosen due to their high significance in the fabrication of the SMMs. The dependent parameters or responses that comprised; particle size (PS), zeta potential (ZP) and mean dissolution time (MDT) were sought, as presented in Table 1 . Fifteen formulations were generated from the Box-Behnken (Table 2) . These formulations were prepared and experimentally tested and the results obtained were fed into the MINITAB ® design software which then computed the optimized formulation's independent parameter and expected response values. which assessed the degree of reversible colloidal phenomena such as creaming and sedimentation as well as irreversible phenomena such as coalescence and flocculation (Celia et al., 2009 Measurements were performed at 25ºC and the Turbiscan ® Lab was configured to perform continuous scans, performing a scan every 6 minutes, over a 55mm cell length from bottom to top for an hour. Variation in particle volume fraction (Ф) on particle migration (sedimentation of creaming) and the mean particle diameter (d) due to coalescence resulted in variation in the quantity of transmitted and backscattered light. The measured amount of transmitted and backscattered light was then interpreted and used to describe the dispersion state (stability) of the emulsion (Mengual et al., 1999; Lemarchand et al., 2003; Celia et al., 2009 ).
Morphological characterization of the SMMs
The shape and surface morphology of the SMMs were determined using a transmission electron microscope (TEM, JEOL S100 Transmission Electron Microscope, Tokyo, Japan) set at 40 000X magnification. The particle size of the SMMs was determined by measuring particle diameter through a process of dynamic light scattering using a Zetasizer (Zetasizer Nano ZS, Malvern Instruments Ltd, Worcestershire, United Kingdom). Particle surface charge was evaluated by measuring the zeta potential of the SMMs using the Zetasizer (Garcia et al., 2011) . SMM powder (5mg) samples were each dispersed in 30mLs of MilliQ water and passed through 0.22µm Minisart ® non-pyrogenic single use filters (Sartorius Stedim Biotech, Goettingen, Germany) into quartz cuvettes and specialized zeta potential containers respectively which were then inserted into the Zetasizer to determine particle size and zeta potential (Garcia et al., 2011) . 
Fourier transform infrared (ATR-FTIR) spectroscopy analysis
Thermal analysis
The thermal properties of PEC, MUC, AZT and the AZT-loaded SMMs were analyzed by DSC. The analysis was conducted on a differential scanning calorimeter (Mettler Toledo, DSC1, STARe System, Schwerzenback, Switzerland) which was calibrated for temperature and enthalpy using indium and zinc. All experiments were performed at a heating rate of 10°C min -1 under a dry nitrogen atmosphere (Afrox, Germiston, Gauteng, South Africa) which flowed at a rate of 200mLmin -1 acting as the purge gas in order to reduce sample oxidation. Samples were placed in 40μL aluminium pans and heated from -10°C to 110°C
and kept at 110°C for 3 minutes. This was done to evaporate any moisture in the sample and to eliminate any thermal history. The samples were then quenched from 110°C to -10°C at a rate of 20°C min -1
. The midpoint melting point (T m ) and heat of fusion (ΔH) which were used for characterization were obtained from the melting point depression of the peaks generated on the experimental DSC curves on heating the samples from -10 to 300°C.
Thermogravimetric analysis
Thermal degradation analysis was performed on 10-20mg samples of PEC, MUC, AZT and AZT-loaded PEG-encl-PEC:MUC SMMs which were contained in ceramic pans under nitrogen atmosphere using a TGA 4000 thermogravimetric analyzer (PerkinElmer Inc., Massachusetts, USA). The experiments were run at 10°Cmin -1 from 50-500°C.
Thermograms obtained and their first derivatives revealed the thermal degradation properties of the samples.
X-ray diffraction analysis
The crystalline and amorphous nature of the AZT-loaded SMMs and their individual compositional components was investigated using a Rigaku MiniFlex600 Benchtop X-ray Diffractometer (Rigaku Corporation, Tokyo, Japan) fitted with; a 600W (40Kv-15mA) X-ray generator, a counter monochromator to cut X-rays other than Cu Kα X-rays and a high intensity D/tex ultra-high speed 1D detector. Experimental temperature was maintained at 19ºC. The diffractometer was operated using the Rigaku MiniFlex Guidance software, version 1.2.0.0 and data was analyzed using the Rigaku PDXL Basis software able to perform integrated intensity calculations. Measurement parameters included a divergence slit (DS) of 1.25º, scattering slit (SS) of 1.25º, a 0.3mm receiving slit (RS) and a goniometer radius of 150mm. Each powder sample of PEC, MUC, AZT and AZT-loaded PEG-encl-PEC:MUC SMMs was pressed flat onto a square grooved glass slide sample holder.
Measurements were performed by scanning each sample at 0.01-100º/min over a diffraction angle range of 3º-60º 2θ. The XRD diffractograms generated were used to evaluate the crystallinity of the respective samples Mishra et al., 2008; Kumar et al., 2010; Raviolo and Briñón, 2011) .
Drug encapsulation and release from SMMs
The percentage encapsulation efficiency (EE) of the optimized SMMs was determined according to Eq. 3 (Garcia et al., 2011) .
Where, the actual amount of AZT in SMMs was measured on a 100mg sample. SMMs (100mg) were added to 100mL of MilliQ water, ultrasonicated for 10 minutes, vortexed for 5 minutes and then allowed to release the remaining AZT form the SMMs over 48 hours whilst in an orbital shaker bath that rotated at 20rpm and was set at 37ºC. The amount of AZT that was encapsulated in the SMMs was then computed form the UV absorbance values measured using a nanophotometer (NanoPhotometer TM , Implen GmbH, Munchen, Germany)
at ambient temperature (25°C) and at a UV absorbance lambda max of 267nm.
Determination of EE was performed in triplicate. The theoretical amount of AZT was the proportional amount of AZT in the 100mg of SMMs in reference to the loading dose. AZT release from PEG-encl-PEC:MUC SMMs was performed using the dialysis membrane technique over 24 hours in a 100mL container filled with SVF (Gupta et al., 2011; Woolfson et al., 2010; Shaikh et al., 2009) . The dissolution media (simulated vaginal fluid, SVF), was prepared according to Owen and Katz's as presented in Table 3 (Owen and Katz, 1999) .
The drug-loading capacity was computed accordingly based on the various drug:polymer ratios. Drug release was also performed in phosphate buffered saline (PBS pH 7.4) which acted as simulated semen (Gupta et al., 2011; Woolfson et al., 2010; Owen and Katz, 2005) . The AZT-loaded SMMs and 2mLs SVF or PBS (similar medium as the bulk 100mL dissolution medium) were added into a dialysis tubing which had a molecular weight cut off of 12kDa
obtained from Sigma-Aldrich Inc., St. Louis, USA) (Gupta et al., 2011; Shaikh et al., 2009 ).The tubing was securely tied at both ends and then suspended in a dissolution media filled 100mL container that was placed in an orbital shaker incubator (Orbital Shaker
Incubator, LM-530D, Yihder Technology CO., LTD, Jhonghe City, Taipei County, Taiwan, Republic of China) which was set at 37°C and rotated at 20rpm (Woolfson et al., 2010) .
Dissolution media aliquots (200µL) were withdrawn at predetermined time intervals and Ultraviolet (UV) quantification of the amount of drug released was performed using the nanophotometer. Dissolution tests were performed in triplicate. Dissolution profiles were generated from the amounts of AZT released over 24 hours and these profiles were used to characterize in vitro AZT release kinetics from the SMMs. The ability of the macromolecular SMMs to modulate AZT release was evaluated by determining the mean dissolution time (MDT) according to Eq. 4 and the dissolution efficiency (DE) which is the area under the dissolution curve up to a certain time, t, expressed as a percentage of the rectangular area described by 100% dissolution in the same time, according to Eq. 5 (Khan, 1975; Costa and Lobo, 2001, Garcia et al., 2011) .
∑
Where M t is the fractional dose released in time t i = (t i +t i-1 )/2 and M ∞ corresponds to the loading dose
∫
Where y is the percentage of drug dissolved at time t. The pH responsiveness of the SMMs was tested by comparing the dissolution efficiencies, MDTs and computing the similarity factor (f 2 ) and the difference factor (f 1 ) of the dissolution profiles obtained in SVF and in PBS according to Eqs. 6 and 7 (Moore and Flanner, 1996; O'Hara et al., 1998; Costa et al., 2001; Zhang et al., 2010) .
Where n is the number of sampling points, W t is an optional weight factor, R t is the reference assay at time t and T t is the test assay at time t. The dissolution profile of the PEG-encl-PEC:MUC SMMs in SVF and in PBS was fitted into 14 different kinetic models. The best fit parameters and the adjusted coefficient of determination (R 2 adjusted ), which is regarded as the goodness of fit parameter, was obtained. R 
Results and Discussion
Preparation and optimization of the macromolecular SMMs
All 15 formulations from the design template produced SMMs of varying particle size, zeta potential and had different MDTs (Table 4) showed no significant difference among the formulations, these two parameters were not included as responses during formulation optimization. Linear regression of independent parameters and responses using MINITAB ® generated relationships described by the polynomial Eqs. 8, 9, and 10 ( Karnachi and Khan, 1996 
The correlation of the independent parameters; ST, SC and D:P ratio to the responses; PS, ZP and MDT was further illustrated as response mesh plots presented in Fig. 1 (Karnachi and Khan, 1996) . 
Sub-microsphere emulsion stability
The delta transmission and delta back scattering profiles of the optimised SMM emulsion depicted in Fig. 2 shows that the SMM emulsion was generally stable with some local destabilization (sedimentation) as observed by the gradual decrease in the delta backscattering (DeltaBS) signal at the top end of the glass cell. The middle and the left of the profile was relatively unchanged which meant that the emulsion was stable over the hour long test duration and no global destabilization (coalescence) and no creaming occurred to the SMM emulsion during the total experimentation duration (Fig. 2) . During the SMM synthesis the emulsion is centrifuged within an hour followed by freezing at -80 degrees for 24 hours then lyophilized for 48 hours, therefore the minimum sedimentation that occurs as observed in Fig. 2 does not significantly affect the AZT-loaded PEG-encl-PEC:MUC SMM formulation.
Morphological characterization of AZT-loaded PEG-encl-PEC:MUC SMMs
Well defined spherical SMMs were observed under TEM (Fig. 3) . The mean particle size of the SMMs prepared from the 15 design formulations ranged from 143.6±21.110nm, F3, to 321.1±17.370nm, F15, ( Table 4 ). The optimized formulation had a mean particle size of 270.6±5.53nm and had a stable polydispersity index (PDI) of 0.303±0.028 as depicted in Fig.   4a . Zeta potential for the 15 design formulations ranged from -28.1±0.894mV to -47.4±0.536mV (Table 4 ). The optimized formulation had a zeta potential of -34.4±0.539mV
signifying that the SMMs were not agglomerated (Fig. 4b) . 
ATR-FTIR analysis of components and the AZT-loaded PEG-encl-PEC:MUC SMMs
FTIR spectrum of PEG-encl-PEC:MUC SMMs (Fig. 5 ) revealed a broad absorption peak extending from approximately 3000-3600cm -1 due to the overlapped stretching vibrations of hydroxyl (-OH) groups present in MUC, PEC, AZT and PEG and the carboxyl (-COOH) groups of PEC and MUC (Kumar et al., 2010; Mashingaidze et al., 2013) . The broadening of this peak as compared to those in PEC (Fig. 5c) , MUC (Fig. 5b) , PEG ( Fig. 5e ) and AZT ( Fig. 5d ) was due to the participation of the -OH and COOH groups in H-bonding. The SMM absorption peaks observed at 2933cm -1 and 2854cm -1 were attributed to strong stretching vibrations of the alkane groups; -CH 3 , -CH 2 , and -CH that are found in PEC (peak 2935cm ).
AZT encapsulation in PEG-encl-PEC:MUC SMM was confirmed by the presence of the absorption peak at 2105cm -1 which was assigned to the stretching vibrations of the azide (-N 3 ) group of AZT (Fig. 5a ). The reduction in intensity of this peak as compared to those observed on the AZT ATR-FTIR spectrum (Fig. 5d ) resulted from shielding of AZT as it was encapsulated within the PEG-encl-PEC:MUC SMMs and due to the participation of the -N 3
group in H-bonding with -OH and -COOH groups found in PEC, MUC and PEG. The peak that was observed at 1742cm -1 on the AZT-loaded PEG-encl-PEC:MUC SMM ATR-FTIR spectra (Fig. 5a) ) and AZT, peak 1641cm -1 and 1670cm -1 (Patel et al., 2003; Tam et al., 2005) . The ATR-FTIR spectra of SMMs, PEC, MUC, PEG and AZT depicted several peaks in the finger-print region (1450-650cm) which were consistent with what is reported in literature and expected for the AZT-loaded SMMs (Mishra et al., 2008; Patel et al 2003; Ravi et al., 2008) . No apparent differences were observed between the FTIR spectra of drug-loaded and drug-free PEG-encl-PEC:MUC SMMs except for the presence of vibrational peaks corresponding to AZT in the former. 
Assessment of differential scanning calorimetry profiles
DSC thermograms of AZT-loaded PEG-encl-PEC:MUC SMMs, MUC, PEC and AZT are depicted in Fig. 6 . AZT-loaded PEG-encl-PEC:MUC SMMs had a broad endothermic peak with melting point peak maxima at 113.67°C and a measured heat of fusion of 9.75Jg -1 as well as an exothermic crystallization peak at 230.81°C (Fig. 6a) . SMM components; MUC had an melting point represented by an endothermic peak maxima at 101.36°C (Fig. 6b ), PEC had a melting endothermic peak at 120.73°C as well as an exothermic crystallization peak at 236.17°C (Fig. 6c) and the model drug, AZT, had an onset melting point at 122.88°C
and an exothermic crystallization peak at 240.34°C (Fig. 6d ) that were consistent with results reported in literature (Araújo et al., 2003) . The thermal DSC thermogram of AZT-loaded PEG-encl-PEC:MUC SMMs confirms SMM composition and was a result of the thermal contribution of PEC, MUC, PEG and AZT. 
Thermogravimetric analysis of AZT loaded SMMs and their native constituents
The thermal degradation of AZT-loaded PEG-encl-PEC:MUC SMMs as measured by TGA produced the thermogram depicted in Fig. 7a (solid) . The SMM TGA thermogram depicts indistinctive one-step degradation with weight loss of approximately 84% on heating from 50-500°C. However, its first derivative TGA (DTGA, dotted) revealed that the SMMs degraded in three major steps as revealed by DTGA peaks at 239.60°C, 287.90°C and 409.77°C that correspond to the points of inflection on the SMM TGA thermogram. It is vital to compare the SMM TGA thermogram with that of all the components from which the SMMs were formulated i.e. PEC, MUC, PEG and AZT as presented in Fig. 7b . Fig. 7c shows the TGA (solid) and DTGA (dotted) thermograms of PEC. Thermal degradation of PEC was shown to take place in two steps; the first was a minor step that took place from 50-150°C resulting in 7.919% weight loss and a point of inflection at 95.03°C which may have been a result of dehydration. The second and major PEC degradation step had an extrapolated onset and end at 233.54°C and 276.92°C respectively with its point of maximum degradation represented by the DTGA (peak 246.01°C). This second degradation step resulted in a weight loss of approximately 59% and was most likely due to the depolymerization of PEC carbohydrate chains (Kumar et al., 2010) . PEC weight loss of approximately 66.98% was experienced from 50-500°C. The first DTGA peaks of the SMMs, 239.60°C (Fig. 7a) and PEC, 246.01°C (Fig. 7c ) are observed to be close; therefore, PEC degradation might have contributed to the initial degradation of the SMMs (Fig. 7a ).
Thermal degradation of MUC was also observed to occur in two steps, with the first minor step occurring from 50-150°C which resulted in a corresponding DTGA peak at 90.63°C that resulted in weight loss of approximately 9.14% (Fig. 7d ). This step was likely a result of the evaporation of bound water molecules from the MUC macromolecules. This first step was then followed by a major degradation step which had an extrapolated onset and end at 264.58°C and 330.64°C respectively with its point of inflection corresponding to the DTGA peak at 286.50°C. This major degradation step was possibly a result of the depolymerization of oligosaccharide side-chains in MUC. Overall, there was a total weight loss of 66.17% on heating MUC from 50-500°C. Due to the closeness of the DTGA peaks of the corresponding second degradation steps of MUC, peak at 286.50°C (Fig. 7d) and SMMs, peak at 287.90°C
( Fig. 7a) , MUC was likely a contributor to the second degradation step of the AZT-loaded PEG-encl-PEC:MUC SMMs (Fig. 7a) .
The model drug, AZT, thermally degraded in two major steps depicted by the DTGA peaks and the total AZT weight loss on heating from 50-500°C was 77.935%. The third degradation step of the SMMs, DTGA peak 409.77°C (Fig. 7a) was likely due to the degradation of PEG which degraded almost completely (99.084%) in one major step with an extrapolated onset and end of 338.89°C and 393.97°C respectively (Fig. 7f) . The point of maximum degradation of PEG corresponds to the DTGA peak at 395.15°C (Fig. 7f ).
All the three degradation steps of the SMMs were shifted to the right as compared to the corresponding degradation steps of the respective components of the SMMs (PEC, MUC, AZT and PEG) signifying SMM thermal stability. The SMM thermal stability might have been brought about by the macromolecular ionic crosslinking using Ca 2+ done in formulation of the SMMs as well as the intermolecular interactions possibly due to hydrogen bonding of the carboxyl, hydroxyl, amide, amine and azide groups of the SMM components. several sharp peaks that include major peaks at 2θ equal to 8.725º, 14.535º, 15.374º, 15.726º, 16.987º, 21.265º, 22.093º, 24.064º, 26.825º, 27.677º, 29.181º and 29.181º which signify the crystalline nature of the AZT-loaded PEG-encl-PEC:MUC SMMs (Fig. 8a) . The diffractogram of PEC depicts a broad peak at 2θ equal to 21.274º indicating the amorphous nature of PEC (Fig. 8c ) and the difractogram of MUC depicts a broad peak at 2θ equal to 21.525º illustrating also the amorphous nature of MUC (Fig. 8b) . AZT was shown to be crystalline by several sharp peaks that include major peaks at 2θ equal to 9.000º, 14.891, 15.725º, 16.040º, 17.304º, 21.41º, 21.640º, 24.513º, 27.140º, 28 .050º and 29.500º observed on its diffractogram shown in Fig. 8d which are similar to the ones previously reported by Raviolo and Briñón (Raviolo and Briñón, 2011) . The observed patten in the diffractograms in Fig. 8 shows that the crystallinity of AZT-loaded PEG-encl-PEC:MUC SMMs was a result of the contribution by the highly crystalline AZT. The peaks observed in the diffractogram of AZT-loaded PEG-encl-PEC:MUC SMMs were sharp as those observed for AZT but were shifted slightly to the left by less than 1º and peak intensities were lower than those of observed for AZT which was probably because of the formation of a less crystaline complex when AZT was ecapsulated in the amorphous MUC and PEC based SMMs (Mishra et al., 2008; Santos et al., 2003 , Shaikh et al., 2009 . 
In vitro drug release from PEG-encl-PEC:MUC SMMs
The release of AZT from SMMs in SVF occurred mostly within 24 hours for the 15 BoxBehnken design formulations as depicted in the dissolution profiles in Fig. 9 . The ability of the macromolecular SMMs to retain drug and prolong drug release was evaluated using the MDT. The MDT varied from 3.573 hours for formulation F3 to 6.300 hours for formulation F7 (Table 4 ). The optimized formulation had a MDT of 5.974 hours. Comparative drug release of the optimized formulation in PBS pH 7.4 yielded a MDT of 5.389 hours (Fig. 9d) . Drug release from the optimized SMMs within 24 hours in SVF pH 4.5 was approximately 91% as compared to approximately 94% in PBS (Fig. 9d) . An increase in pH from acidic (pH 4.5 SVF) to alkaline (pH 7.4 PBS) might have caused a destabilization in the architecture of the SMMs leading to increased leakage of the encapsulated drug as shown by the increase in the fractional drug release in PBS as compared to that seen in SVF in Fig. 9d . Additionally, the mean dissolution time for the drug released from the SMMs was shorter in PBS as compared to SVF. This variation in drug release in dissolution media of different pH may be explained by the presents of carboxyl groups in pectin and mucin which are neutral in an acidic environment (SVF; pH4.5) and but ionized in an alkaline environment (PBS pH 7.4) which would lead to repulsion of the negatively charged moieties thus causing an architectural destabilization of the SMMs leading to increased drug release and a decreased mean dissolution time. However, the effect appeared not too pronounced possibly because pectin and mucin were interpenetrated and crosslinked. This was also confirmed by the similarity of the SMM dissolution profiles obtained in SVF and in PBS as specified by the closeness of their dissolution efficiencies (DE =69.097% in SVF and DE=73.568% in PBS) and according to the computed similarity and difference factors (f 2 =63.132 and f 1 =8.099) (Moore and Flanner, 1996; O'Hara et al., 1998; Costa et al., 2001; Zhang et al., 2010) . From the dissolution profiles in Fig. 10 , it was noted that ionic crosslinking PEC with Ca 2+ reduced the amount of drug released in 24 hours and this may have been a result of the formation of an egg-box network structure when the Ca 2+ electrostatically interacted with the carboxylic moieties of the macromolecular PEC (Yu et al., 2009 ). This egg-box structure condenses the PEC chains encapsulating AZT leading to reduced dissolution. PEG caused a slight increase in the amount of drug released and this may have occurred because PEG draws water molecules towards the SMMs by forming hydrogen bonds to the surrounding water molecules from the dissolution media, SVF or PBS). k0, k1, kH, kKP, n, kKP, kHC, kHB, kBL, k, k2, α and β are best fit parameters of the respective dissolution models
Modeling of the dissolution in SVF and PBS showed that AZT release kinetics fitted with most kinetics models tested as given by the values of the adjusted coefficient of determination (R 2 adjusted ) with the exception of the zero order kinetic model as shown in Table  5 . The highest goodness of fit parameter (R 2 adjusted ) was attained using the Logistic and Makoid-Banakar models for the dissolution profiles obtained in SVF and PBS, respectively.
The closeness of the best fit parameters and R 2 adjusted underline the similarity in the SMMs dissolution kinetics and profiles when dissolution was performed in SVF (pH 4.5) as compared to dissolution in PBS (pH 7.4).
Conclusions
AZT-loaded PEG-encl-PEC:MUC submicron matrices were successfully formulated. A BoxBehnken design optimization was performed for the submicron matrices. The optimised submicron matrices prepared by a crosslinking-emulsion technique were spherical and not agglomerated. Drug release studies performed over 24 hours showed that approximately 91% and 94% of AZT was released in SVF and PBS (which acted as simulated semen), respectively. Drug release kinetics of the submicron matrices were found to fit most models tested with the highest goodness of fit parameter (R 2 adjusted ) being observed with the Logistic and Makoid-Banakar models for the dissolution profiles obtained in SVF and PBS, respectively.
